|
[1]SAXENA NK, ANANIA FA.Adipocytokines and hepatic fibrosis[J].Trends Endocrinol Metab, 2015, 26 (3) :153-161.
|
|
[2]LEONARDI F, MARIA N, VILLA E.Anticoagulation in cirrhosis:A new paradigm?[J].Clin Mol Hepatol, 2017, 23 (1) :13-21.
|
|
[3]WANLESS IR, WONG F, BLENDIS LM, et al.Hepatic and portal vein thrombosis in cirrhosis:Possible role in the development of parenchymal extinction and portal hypertension[J].Hepatology, 1995, 21 (5) :1238-1247.
|
|
[4]JAIRATH V, BURROUGHS AK.Anticoagulation in patients with liver cirrhosis:Complication or therapeutic opportunity?[J].Gut, 2013, 62 (4) :479-482.
|
|
[5]SEKI E, SCHWABE RF.Hepatic inflammation and fibrosis:Functional links and key pathways[J].Hepatology, 2015, 61 (3) :1066-1079.
|
|
[6]HELLEBRAND C, WILKENS G, KOHL J, et al.Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans[J].Nat Genet, 2005, 37 (8) :835-843.
|
|
[7]TRIPODI A, PRIMIGNANI M, CHANTARANGKUL V, et al.An imbalance of pro-vs anti-coagulation factors in plasma from patients with cirrhosis[J].Gastroenterology, 2009, 137 (6) :2105-2111.
|
|
[8]SIMONETTO DA, YANG HY, YIN M, et al.Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces[J].Hepatology, 2015, 61 (2) :648-659.
|
|
[9]CHAMBERS RC.Abnormal wound healing responses in pulmonary fibrosis:Focus on coagulation signalling[J].Eur Respir Rev, 2008, 17 (109) :130-137.
|
|
[10]OWENS AP, MACKMAN N.Tissue factor and thrombosis:The clot starts here[J].Thromb Haemost, 2010, 104 (3) :432-439.
|
|
[11]RAUTOU PE, TATSUMI K, ANTONIAK S, et al.Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury[J].J Hepatol, 2016, 64 (1) :53-59.
|
|
[12]MOCHIDA S, ARAI S, YAMANOBE F, et al.Anticoagulant targeting for hepatic sinusoidal walls in prevention of hypercoagulopathy in cold preserved rat livers[J].Transplant Proc, 1998, 30 (1) :45-48.
|
|
[13]CALVARUSO V, MAIMONE S, GATT A, et al.Coagulation and fibrosis in chronic liver disease[J].Gut, 2008, 57 (12) :1722-1727.
|
|
[14]CAMERER E, HUANG W, COUGHLIN SR.Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa[J].Proc Natl Acad Sci U S A, 2000, 97 (10) :5255-5260.
|
|
[15]NAULT R, FADER KA, KOPEC AK, et al.From the cover:Coagulation-driven hepatic fibrosis requires protease activated receptor-1 (PAR-1) in a mouse model of TCDD-elicited steatohepatitis[J].Toxicol Sci, 2016, 154 (2) :381-391.
|
|
[16]KITASATO L, YAMAOKA-TOJO M, HASHIKATA T, et al.Factor Xa in mouse fibroblasts may induce fibrosis more than thrombin[J].Int Heart J, 2014, 55 (4) :357-361.
|
|
[17]HOWELL DCJ, GOLDSACK NR, MARSHALL RP, et al.Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis[J].Am J Pathol, 2001, 159 (4) :1383-1395.
|
|
[18]BORENSZTAJN K, von der THUSEN, JAN H, et al.The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis:A multifaceted paradigm[J].J Cell Mol Med, 2010, 14 (1-2) :143-153.
|
|
[19]FIORUCCI S, ANTONELLI E, DISTRUTTI E, et al.PAR1 antagonism protects against experimental liver fibrosis.Role of proteinase receptors in stellate cell activation[J].Hepatology, 2004, 39 (2) :365-375.
|
|
[20]RUPPERT C, MARKART P, WYGRECKA M, et al.Role of coagulation and fibrinolysis in lung and renal fibrosis[J].Hamostaseologie, 2008, 28 (1-2) :30-36.
|
|
[21]ATKINSON JM, PULLEN N, Da SILVA-LODGE M, et al.Inhibition of thrombin-activated fibrinolysis inhibitor increases survival in experimental kidney fibrosis[J].J Am Soc Nephrol, 2015, 26 (8) :1925-1937.
|
|
[22]MERCER PF, CHAMBERS RC.Coagulation and coagulation sig-nalling in fibrosis[J].Biochim Biophys Acta, 2013, 1832 (7) :1018-1027.
|
|
[23]HOEKSTRA J, GUIMARAES AH, LEEBEEK FW, et al.Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome[J].Blood, 2010, 115 (2) :388-395.
|
|
[24]BORENSZTAJN K, CONG L, FRANCOIS C, et al.Coagulation factor IX deficiency does not afford protection from pulmonary fibrosis in the experimental murine bleomycin model[J].Eur Respir J, 2012, 40:3670.
|
|
[25]WILBERDING JA, PLOPLIS VA, MCLENNAN I, et al.Development of pulmonary fibrosis in fibrinogen-deficient mice[J].Ann N Y Acad Sci, 2001, 936 (1) :542-548.
|
|
[26]RAMACHANDRAN R, NOORBAKHSH F, DEFEA K, et al.Targeting proteinase-activated receptors:Therapeutic potential and challenges[J].Nat Rev Drug Discov, 2012, 11 (1) :69-86.
|
|
[27]CHAMBERS RC.Role of coagulation cascade proteases in lung repair and fibrosis[J].Eur Respir J, 2003, 22 (44) :33-35.
|
|
[28]MARIA ME, MAR A TM, ANTONIO JRA, et al.Inflammatory status in human hepatic cirrhosis[J].World J Gastroenterol, 2015, 21 (41) :11522-11541.
|
|
[29]SENZOLO M, M SARTORI T, ROSSETTO V, et al.Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis[J].Liver Int, 2012, 32 (6) :919-927.
|
|
[30]CERINI F, VILASECA M, LAFOZ E, et al.Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats[J].J Hepatol, 2016, 64 (4) :834-842.
|
|
[31]WANG BY, ZHAO W, NIU XM, et al.Mechanism of action of Yiqi Huoxue Recipe in regulating autophagy and reversing liver fi-brosis[J].Chin J Hepatol, 2017, 25 (5) :365-370. (in Chinese) 王宝玉, 赵文, 牛学敏, 等.益气活血方调节自噬及逆转肝纤维化机制的研究[J].中华肝脏病杂志, 2017, 25 (5) :365-370.
|
|
[32]XIE XC, LIU MH, ZHAO SH, et al.Assessment of therapeutic effect of nuemu pill in the hepatitis-B liver fibrosis[J].J Changchun Univ Chin Med, 2016, 32 (1) :123-125. (in Chinese) 谢湘春, 刘明晖, 赵树华, 等.疟母丸治疗乙型肝炎肝纤维化的效果[J].长春中医药大学学报, 2016, 32 (1) :123-125.
|
|
[33]LI WC, ZHANG JS, ZHU HG, et al.Effect of low anticoagulative activity heparin on the growth of rat hepatic stellate cells[J].J Zhengzhou Univ:Med Sci, 2007, 42 (3) :451-453. (in Chinese) 李文才, 张锦生, 朱虹光, 等.低抗凝肝素对大鼠肝星状细胞生长的影响[J].郑州大学学报:医学版, 2007, 42 (3) :451-453.
|
|
[34]LI CJ, YANG ZH, SHI XL, et al.Effects of aspirin and enoxaparin in a rat model of liver fibrosis[J].World J Gastroenterol, 2017, 23 (35) :6412-6419.
|
|
[35]YAN YS, GUAN CG, DU SS, et al.Effects of enzymatically depolymerized low molecular weight heparins on CCl4-induced liver fibrosis[J].Front Pharmacol, 2017, 8:514.
|
DownLoad: